Login
Navigate Fool.com
Will GILD beat
the market?

Gilead Sciences

NASDAQ: GILD

Community Rating: 4 Stars: Favorite

70.00 0.72 (1.04%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $69.37
Previous Close $69.28
Daily Range $69.09 - $70.64
52-Week Range $46.70 - $84.88
Market Cap $107.7B
P/E Ratio 38.67
Dividend (Yield) $0.00 (0.0%)
Volume 17,548,425
Average Daily Volume 19,329,828
Current FY EPS $3.92

How do you think GILD
will perform against the market?

Top GILD Bull/Bear Pitches

 

CarolinaMatt (< 20)
Submitted January 3, 2011

Yes I get it. This company is no longer the high-flying early-stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution. But this is no old super-slow … More

0 Replies Reply Report this Post
 

stockfreak1 (19.13)
Submitted July 24, 2010

With more and more HIV generics around the corner it's not surprising why the CEO is selling and selling quick. Anyone actually see the retail prices on their drugs? Good God Viread is like $12 a pill … More

0 Replies Reply Report this Post

News & Commentary

3 Reasons the Market Is Down on Gilead Sciences

Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Slow growth from medical device and consumer goods masked robust sales in Johnson & Johnson's drug business.

Has A Streamlined FDA Raised The Value Of Drug Stocks?

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Here's what you need to know about Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) before they report their first quarter earnings later this month.

If This Biotech Drops Much Further I'm Going to Buy It!

This biotech behemoth dipped by more than 20% recently despite a growth rate that could easily equal 25% over the next five years. Needless to say, if it drops any further I'm going to buy it!

Noteworthy ETF Outflows: VHT, GILD, MDT, ESRX

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

Gilead Sciences' oral hepatitis C drug Sovaldi has taken the market by storm, but Merck's looking to fight back in the race to capture this lucrative niche.

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides

Is the plummeting valuation justified?

3 Stocks to Get on Your Watchlist

Gilead Sciences, Silver Wheaton, and Rite Aid are this week's must-watch stocks.

Johnson and Johnson Earnings Surprises With Blockbuster Potential

11% growth in pharmaceuticals drives top-line growth at JNJ. But one drug really stole the show.

See More GILD News...

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks